Pasithea Therapeutics Corp NASDAQ:KTTA:
ANNOUNCES POSITIVE INTERIM PHASE 1 ADVANCED CANCER STUDY DATA DEMONSTRATING LONG-TERM SAFETY AND TOLERABILITY, AND DURABLE CLINICAL ACTIVITY IN MEK/BRAF-PRETREATED PATIENTS, PLUS PROTOCOL EXPANSION
PAS-4 SHOWS FAVORABLE SAFETY PROFILE WITH ONLY GRADE 1 OR 2 ADVERSE EVENTS
PROTOCOL AMENDMENT EXTENDS DOSE ESCALATION UP TO 52MG FOR PAS-4
INITIATES PILOT FOOD EFFECT STUDY FOR PAS-4 PHARMACOKINETICS